Enlightenment through smart measurements

Open menu

News & Events

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS

3 October 2018

OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS Quebec City, Quebec, October 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) will host an investor webinar and live Q&A session on Thursday, October 4, 2018, at 4.05 p.m. EST. The webinar will feature a presentation by…

Read more

Opsens Solutions present at the ESREF 2018

28 September 2018

We are going to be happy to meet you at booth 21 – ESREF 2018 – the 29th European Symposium on Reliability of Electron Devices, Failure Physics and Analysis, October 1-5, 2018, at Aalborg, Denmark.

OPSENS – NEW PRODUCT FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST

20 September 2018

Quebec City, Quebec, September 20, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces it has developed a product that will allow the diagnosis of coronary heart blockages with the heart at rest. Filing for regulatory approvals has been completed in targeted territories. Opsens plans to begin commercialization by the end of calendar…

Read more

OPSENS REPORTS Q3 2018 RESULTS – Quarterly Revenues Eclipse $6.4 M

12 July 2018

Quebec City, Quebec, July 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter ended May 31, 2018. Highlights for the quarter Consolidated revenues reached $6,398,000 for the three-month period compared with $4,892,000 for the same period last year, an increase of $1,506,000 or 31%; Consolidated…

Read more

Opsens Solutions have moved in a new improved facilities

30 April 2018

Opsens Solutions is proud to inform that we have moved to a new improved facilities. Our new address is: 319 Franquet Street, Suite 110, Québec City, QC G1P 4R4 Canada. Phone number haven’t change: 418-682-9996 www.opsens-solutions.com

OPSENS APPLAUDS JAPANESE GOVERNMENT NEW REGULATION SUPPORTING DIAGNOSIS, SUCH AS FFR, BEFORE TREATMENT OF CORONARY STENOSIS

24 April 2018

Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as a preferred assessment method. The MHLW recently revised medical…

Read more

OPSENS REPORTS Q2 2018 RESULTS – CONSOLIDATED PRODUCT SALES UP 44%

12 April 2018

Quebec City, Quebec, April 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter ended February 28, 2018. Highlights Consolidated product sales reached $5,352,000 compared with $3,710,000 for the same period last year, an increase of $1,642,000 or 44,3%; Fractional Flow Reserve (“FFR”) revenues reached $3,313,000…

Read more

OPSENS ANNOUNCES ELECTION RESULTS FOR THE BOARD OF DIRECTORS AND THE RETIREMENT OF CLAUDE BELLEVILLE

23 January 2018

  Quebec City, Quebec, January 23, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today held its annual general shareholders’ meeting (the “Meeting”) at its head office in Quebec City, Canada. Opsens’ shareholders re-elected Denis M. Sirois, Denis Harrington, Pat Mackin, Jean Lavigueur, Gaétan Duplain and Louis Laflamme as members of the Board…

Read more

OPSENS REPORTS Q1 2018 RESULTS – RECORD QUARTERLY REVENUES WITH GROWTH IN ALL GEOGRAPHIC REGIONS

16 January 2018

Quebec City, Quebec, January 15, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the first quarter ended November 30, 2017. Highlights Consolidated revenues reached $6,364,000 for Q1 2018 compared with $3,745,000 for the same period last year, an increase of $2,619,000 or 70%; Fractional Flow Reserve (“FFR”) revenues…

Read more

OPSENS’ JAPANESE PARTNER ZEON MEDICAL PROCEEDS WITH CONVERSION OF US$2 MILLION DEBENTURE

27 November 2017

Quebec City, Quebec, November 27, 2017 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce the conversion of the US$2 million debenture held by Zeon Medical Inc. (“Zeon Medical”), Opsens’ Japanese partner. Zeon Medical has been a client of Opsens since 2004. In 2012, Opsens granted Zeon Medical the exclusive distribution rights for…

Read more